ArticleRevista medica del Instituto Mexicano del Seguro Social2026
[Hepatic encephalopathy from cholangitis in a young patient with ornithine transcarbamylase mutation].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic encephalopathy (HE) is a serious neurological complication of chronic liver failure characterized by alterations of consciousness ranging from mild confusion to coma; and although it is classically associated with hyperammonemia secondary to hepatic dysfunction, in some patients genetic or metabolic susceptibilities may coexist. Clinical case: This report presents a 37-year-old male patient who was admitted to the emergency department due to altered mental status, severe hyperbilirubinemia, acute renal dysfunction, and signs of decompensated liver failure; therefore, the diagnosis of hepatic encephalopathy triggered by cholangitis was established. During hospitalization, the patient exhibited disproportionate hyperammonemia relative to the degree of hepatic dysfunction, and genetic analysis revealed a heterozygous variant in the ornithine transcarbamylase (OTC) gene and multidisciplinary treatment was initiated to reduce ammonia. Conclusion: This case allows us to reflect on the diagnostic and therapeutic challenges of HE, as well as the importance of a comprehensive approach in patients with advanced liver disease. Furthermore, it demonstrates how genetic defects of the urea cycle, such as partial OTC deficiency, can aggravate hyperammonemia and encephalopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.